Galapagos Stock Forecast, Price & News

-0.08 (-0.10 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $77.81
50-Day Range
MA: $81.48
52-Week Range
Now: $77.81
Volume198,860 shs
Average Volume295,824 shs
Market Capitalization$5.10 billion
P/E RatioN/A
Dividend YieldN/A
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, and psoriatic arthritis. The company's clinical stage programs also comprise GLPG1205, a GPR84 inhibitor for treating idiopathic pulmonary fibrosis (IPF); and GLPG4716, a chitinase inhibitor for the treatment of IPF. In addition, it engages in the development of Toledo molecules, including GLPG3970, GLPG3312, GLPG4399, GLPG4876, and GLPG4605 for inflammation; GLPG3667, a TYK2 kinase inhibitor for inflammation; and GLPG3121, a JAK1/TYK2 inhibitor for inflammation. Further, the company develops GLPG1972 for osteoarthritis; GLPG2737, a cystic fibrosis transmembrane conductance regulator inhibitor to treat patients with autosomal dominant polycystic kidney disease; GLPG4586 for fibrosis; and GLPG4059 for treatment of metabolic diseases. It has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Galapagos logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GLPG
Year FoundedN/A



Sales & Book Value

Annual Sales$1.00 billion
Cash Flow$4.84 per share
Book Value$58.75 per share


Net Income$167.83 million


Market Cap$5.10 billion
Next Earnings Date5/6/2021 (Estimated)


Galapagos names new COO and President - Seeking Alpha
March 25, 2021 |
Galapagos (NASDAQ:GLPG) Reaches New 12-Month Low at $79.49
March 23, 2021 |
See More Headlines


Overall MarketRank

1.33 out of 5 stars

Medical Sector

749th out of 2,010 stocks

Pharmaceutical Preparations Industry

361st out of 769 stocks

Analyst Opinion: 4.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.08 (-0.10 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLPG News and Ratings via Email

Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Galapagos (NASDAQ:GLPG) Frequently Asked Questions

Is Galapagos a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 2 sell ratings, 11 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Galapagos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View analyst ratings for Galapagos
or view top-rated stocks.

What stocks does MarketBeat like better than Galapagos?

Wall Street analysts have given Galapagos a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Galapagos wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Galapagos' next earnings date?

Galapagos is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Galapagos

How has Galapagos' stock price been impacted by COVID-19?

Galapagos' stock was trading at $186.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GLPG stock has decreased by 58.2% and is now trading at $77.81.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GLPG?

17 analysts have issued 1-year target prices for Galapagos' stock. Their forecasts range from $94.00 to $290.00. On average, they expect Galapagos' stock price to reach $143.73 in the next year. This suggests a possible upside of 84.7% from the stock's current price.
View analysts' price targets for Galapagos
or view top-rated stocks among Wall Street analysts.

Who are Galapagos' key executives?

Galapagos' management team includes the following people:
  • Mr. Onno Van De Stolpe, Co-Founder, Chairman of the Management Board, MD & CEO (Age 62, Pay $4.29M)
  • Mr. Bart Filius M.B.A., MBA, Pres, COO & Member of Management Board (Age 51, Pay $3.82M)
  • Dr. Andre Hoekema, Chief Bus. Officer & Member of Management Board (Age 64, Pay $3.67M)
  • Dr. Piet Wigerinck, Chief Scientific Officer & Member of Management Board (Age 57, Pay $2.49M)
  • Dr. Walid Abi-Saab, Chief Medical Officer & Member of Management Board (Age 56, Pay $2.55M)
  • Mr. Michele Manto M.B.A., Chief Commercial Officer & Member of Management Board
  • Ms. Elizabeth Goodwin, VP of Investor Relations
  • Ms. Carmen Vroonen, Global Head Communications & Public Affairs
  • John Montana, Managing Director of Argenta
  • Ms. Chantal Tasset, Head of Devel.

What is Onno van de Stolpe's approval rating as Galapagos' CEO?

6 employees have rated Galapagos CEO Onno van de Stolpe on Onno van de Stolpe has an approval rating of 100% among Galapagos' employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Galapagos' key competitors?

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), The Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

When did Galapagos IPO?

(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

What is Galapagos' stock symbol?

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

How do I buy shares of Galapagos?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galapagos' stock price today?

One share of GLPG stock can currently be purchased for approximately $77.81.

How much money does Galapagos make?

Galapagos has a market capitalization of $5.10 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $167.83 million in net income (profit) each year or $5.46 on an earnings per share basis.

How many employees does Galapagos have?

Galapagos employs 1,489 workers across the globe.

What is Galapagos' official website?

The official website for Galapagos is

Where are Galapagos' headquarters?

Galapagos is headquartered at GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800.

How can I contact Galapagos?

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]

This page was last updated on 4/11/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.